Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment

被引：0
|
作者：
Pietrini, F. [1 ]
Spadafora, M. [1 ]
Talamba, G. A. [1 ]
Godini, L. [1 ]
Santangelo, A. [1 ]
Chiarello, F. [1 ]
Ballerini, A. [1 ]
机构：
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Neurosci, Florence, Italy
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
SCHIZOPHRENIA;
D O I：
10.1016/S0924-977X(14)70918-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.013
引用
收藏
页码：S573 / S574
页数：2
相关论文
共 50 条
  • [21] First-generation versus second-generation long-acting injectable antipsychotics in schizophrenia: cognitive impairment
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Sanchez-luengo, F. Gotor
    EUROPEAN PSYCHIATRY, 2019, 56 : S512 - S513
  • [22] Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists
    Jaeger, Matthias
    Rossler, Wulf
    PSYCHIATRY RESEARCH, 2010, 175 (1-2) : 58 - 62
  • [23] Combination of two long-acting injectable antipsychotics in treatment-resistant schizophrenia: A retrospective 12-month mirror-image study
    Calvin, Nathalia
    Minischetti, Laurence
    Salanon, Florent
    Llorca, Pierre-Michel
    Pouchon, Arnaud
    Polosan, Mircea
    Donde, Clement
    ASIAN JOURNAL OF PSYCHIATRY, 2023, 80
  • [24] Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review
    Salgueiro, Monika
    Segarra, Rafael
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (02) : 51 - 56
  • [25] Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review
    Keramatian, Kamyar
    Chakrabarty, Trisha
    Yatham, Lakshmi N.
    CNS DRUGS, 2019, 33 (05) : 431 - 456
  • [26] Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review
    Kamyar Keramatian
    Trisha Chakrabarty
    Lakshmi N. Yatham
    CNS Drugs, 2019, 33 : 431 - 456
  • [27] Long-acting second-generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists
    Corbo, Mariangela
    Martinotti, Giovanni
    Aguglia, Andrea
    Salvi, Virginio
    Amerio, Andrea
    Calo, Salvatore
    Fusar-Poli, Laura
    Serafini, Gianluca
    Signorelli, Maria
    Amore, Mario
    Mencacci, Claudio
    Di Sciascio, Guido
    Biggio, Giovanni
    Aguglia, Eugenio
    Di Giannantonio, Massimo
    PERSPECTIVES IN PSYCHIATRIC CARE, 2021, 57 (04) : 1700 - 1706
  • [28] High Doses of Second-Generation Long-Acting Antipsychotics in the Treatment of Patients with Severe Resistant Schizophrenia: A Six-Year Mirror-Image Study
    Fernandez-Miranda, Juan J.
    Diaz-Fernandez, Silvia
    Lopez-Munoz, Francisco
    PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, 2020, 30 (04) : 335 - 345
  • [29] Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations
    Schoretsanitis, Georgios
    Meyer, Jonathan M.
    Conca, Andreas
    Hiemke, Christoph
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 189 - 202
  • [30] Efficacy, safety and tolerability of long-acting injectable aripiprazole (LAI-Ari) for long-term maintenance treatment in schizophrenia: 12-month prospective cohort study
    Stoimenova, M.
    Chumpalova, P.
    Todorov, A.
    Tumbev, L.
    Kolarov, P.
    Georgiev, G.
    Stoichev, K.
    Veleva, I.
    Popov, P.
    Kirov, K.
    Kozhuharov, H.
    Tonev, R.
    Valtchev, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S561 - S562
12345